Patents Assigned to STEMINA BIOMARKER DISCOVERY, INC.
-
Patent number: 11268966Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).Type: GrantFiled: July 27, 2018Date of Patent: March 8, 2022Assignee: Stemina Biomarker Discovery, Inc.Inventors: Paul West, Robert E. Burrier, Laura Egnash, Alan Smith, Preeti Bais
-
Patent number: 10473641Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.Type: GrantFiled: April 21, 2014Date of Patent: November 12, 2019Assignee: Stemina Biomarker Discovery, Inc.Inventors: Paul R. West, April M. Weir-Hauptman, Alan M. Smith, Elizabeth L. R. Donley, Gabriela G. Cezar
-
Patent number: 10330688Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present or secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provides metabolic signatures of autism, which can be used to provide a diagnosis thereof.Type: GrantFiled: December 7, 2016Date of Patent: June 25, 2019Assignees: Wisconsin Alumni Research Foundation, Stemina Biomarker Discovery, Inc.Inventors: Gabriela Gebrin Cezar, Alan M. Smith
-
Publication number: 20190178900Abstract: With the present invention, metabolomics biomarkers are used to identify subtypes within the autism spectrum disorder (ASD) population. In one embodiment, levels of the metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) of about six times or greater than the median level in typically developing (TD) individuals or about 2 ?M or greater place the individual in an autism subpopulation that includes less than 20% of the total ASD population. Thus, CMPF is a biomarker able to discriminate a subtype of ASD.Type: ApplicationFiled: May 12, 2017Publication date: June 13, 2019Applicants: Stemina Biomarker Discovery, Inc., Stemina Biomarker Discovery, Inc.Inventors: Alan Smith, Paul West, Robert Burrier, Joseph King, Roxana Alexandridis, Laura Egnash, Elizabeth L.R. Donley, Michael Ludwig
-
Patent number: 10209240Abstract: This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.Type: GrantFiled: December 20, 2017Date of Patent: February 19, 2019Assignee: Stemina Biomarker Discovery, Inc.Inventors: Alan Smith, Paul West, Jessica Palmer
-
Patent number: 10060932Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).Type: GrantFiled: July 3, 2014Date of Patent: August 28, 2018Assignee: Stemina Biomarker Discovery, Inc.Inventors: Paul West, Robert E. Burrier, Laura Egnash, Alan Smith, Preeti Bais
-
Patent number: 9547013Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.Type: GrantFiled: April 29, 2011Date of Patent: January 17, 2017Assignees: Wisconsin Alumni Research Foundation, Stemina Biomarker Discovery, Inc.Inventors: Gabriela Gebrin Cezar, Alan M. Smith
-
Publication number: 20150301025Abstract: This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.Type: ApplicationFiled: November 1, 2013Publication date: October 22, 2015Applicant: Stemina Biomarker Discovery, Inc.Inventors: Alan Smith, Paul West, Jessica Palmer
-
Publication number: 20140273069Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.Type: ApplicationFiled: April 21, 2014Publication date: September 18, 2014Applicant: STEMINA BIOMARKER DISCOVERY, INC.Inventors: Paul R. West, April M. Weir-Hauptman, Alan M. Smith, Elizabeth L.R. Donley, Gabriela G. Cezar
-
Patent number: 8703424Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.Type: GrantFiled: March 22, 2011Date of Patent: April 22, 2014Assignee: Stemina Biomarker Discovery, Inc.Inventors: Paul R. West, April M. Weir-Hauptman, Alan M. Smith, Elizabeth L. R. Donley, Gabriela G. Cezar
-
Publication number: 20120190055Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.Type: ApplicationFiled: April 29, 2011Publication date: July 26, 2012Applicants: STEMINA BIOMARKER DISCOVERY, INC., WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Gabriela Gebrin Cezar, Alan M. Smith
-
Publication number: 20110312019Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.Type: ApplicationFiled: March 22, 2011Publication date: December 22, 2011Applicant: Stemina Biomarker Discovery, Inc.Inventors: Paul R. WEST, April M. WEIR-HAUPTMAN, Alan M. SMITH, Elizabeth L.R. DONLEY, Gabriela G. CEZAR
-
Publication number: 20110081675Abstract: The invention provides methods and biomarkers for assessing cardiac metabolic response to pharmaceuticals, environmental agents, chemical compounds and biologic therapies. The invention provides methods for identifying cellular metabolites secreted by primary cardiomyocytes, cardiomyocyte precursor cells, clonal cardiomyocytes derived from adult human heart, immortalized cardiomyocytes, human embryonic stem cell (hESC)-derived cardiomyocytes, human induced pluripotent stem cell (iPS)-derived cardiomyocytes, or any cell displaying cardiomyocyte-specific markers in response to exposure to pharmaceuticals, environmental agents, chemical compounds and biologic therapies that are cardiotoxic. Cardiomyocyte-secreted cellular metabolites provide metabolic signatures of cardiotoxicity, and can be used to screen pharmaceutical agents, lead and candidate drug compounds, biologics, and other therapeutics for cardiotoxic effects.Type: ApplicationFiled: October 6, 2010Publication date: April 7, 2011Applicants: WISCONSIN ALUMNI RESEARCH FOUNDATION, STEMINA BIOMARKER DISCOVERY, INC.Inventors: Gabriela Cezar, Alan Smith